Posted by: Salvatore J. Zambri, Esquire
Medical News Today recently reported that a certain kind of cholesterol–known as lipoprotein (a)–may increase the risk of heart attack (medically referred to as myocardial infarction, or MI). This type of cholesterol, says the article, has been screened little. Historically, doctors have been screening patients for low-denisty lipoproteins, commonly called “bad protein”. Nevertheless, MI has continued to be a leading cause of death. As a result, scientists have been looking at other caused of heart disease.
The theory about lipoprotein (a) leading to heart disease stems from a study of people living in Denmark, who had higher levels of lipoprotein (a) due to genetic reasons, and who were at a higher risk of heart attack. The article comments that the “researchers suggested that although their findings were strong enough to support the idea that higher levels of lipoprotein (a) due to genetic reasons very probably cause higher risk of heart attack, only randomized clinical trials that show fewer heart attacks occur when lipoprotein (a) is reduced through therapy can prove it.” So, expect more studies.
According to the report, representatives of “the National Heart, Lung and Blood Institute’s Framingham Heart Study commented that although Kamstrup and colleagues revealed some ‘interesting mechanistic insights’ into the biological link between lipoprotein (a) and MI, and put forward evidence that there might be potential benefit in reducing lipoprotein (a) early in life, the ‘clinical implications are quite limited.’”
Before taking any medication, we encourage you to seek the advice of competent physicians.
Our firm has experience pursing cases for patients that involve tragic medication errors, pharmacy mix ups and unsafe medications. If you think you have been injured by a defective product, we encourage you to contact the legal team at Regan Zambri & Long for a free consultation.